SLS Shares Plunge 10.09% as 83% AML Trial Success Odds Surface
SLS•Shares of SLS plunged 10.09% in their steepest one-day decline since early June following concerns over its upcoming AML trial. Prediction markets now assign an 83% probability to the November acute myeloid leukemia study achieving success.
1. Stock Experiences Steepest Drop Since June
Shares of SLS tumbled 10.09%, marking the stock’s worst single-day performance in over a month. The decline reflects investor jitters ahead of a pivotal November acute myeloid leukemia trial data release.
2. Prediction Market Signals Strong Trial Outlook
A prediction market currently assigns an 83% probability to SLS’s AML trial succeeding in November, indicating high confidence in positive clinical results. The trial’s outcome could serve as a key catalyst for the company’s share performance.
